• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form DEFA14A filed by Humana Inc.

    3/7/25 7:36:05 AM ET
    $HUM
    Medical Specialities
    Health Care
    Get the next $HUM alert in real time by email
    DEFA14A 1 d852577ddefa14a.htm DEFA14A DEFA14A

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

    SCHEDULE 14A

    Proxy Statement Pursuant to Section 14(a)

    of the Securities Exchange Act of 1934

    (Amendment No. )

    Filed by the Registrant  ☒

    Filed by a Party other than the Registrant  ☐

    Check the appropriate box:

     

    ☐   Preliminary Proxy Statement

      

    ☐ CONFIDENTIAL, FOR USE OF THE COMMISSION ONLY (AS PERMITTED BY RULE 14A-6(E)(2))

    ☐   Definitive Proxy Statement

    ☒   Definitive Additional Materials

    ☐   Soliciting Material Pursuant to §240.14a-12

    Humana Inc.

     

    (Name of Registrant as Specified In Its Charter)

     

     

    (Name of Person(s) Filing Proxy Statement, if other than the Registrant)

    Payment of Filing Fee (Check the appropriate box):

     

    ☒

    No fee required.

     

    ☐

    Fee computed on table below per Exchange Act Rules 14a-6(i)(4) and 0-11.

     

      (1)

    Title of each class of securities to which transaction applies:

     

     

      (2)

    Aggregate number of securities to which transaction applies:

     

     

      (3)

    Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it was determined):

     

     

      (4)

    Proposed maximum aggregate value of transaction:

     

     

      (5)

    Total fee paid:

     

     

     

    ☐

    Fee paid previously with preliminary materials.

     

    ☐

    Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing.

     

      (1)

    Amount Previously Paid:

     

     

      (2)

    Form, Schedule or Registration Statement No.:

     

     

      (3)

    Filing Party:

     

     

      (4)

    Date Filed:

     

     


    On March 7, 2025, Humana Inc. (the “Company”) made the following communication available to the Company’s employees:

    Highlights

     

      •  

    You may have the right to vote on items being presented at our Annual Meeting of Stockholders (the “Annual Meeting”)

     

      •  

    The Company’s Annual Meeting is scheduled for April 17, 2025 at 1:00 p.m. Eastern Time, and will be held via a live audio webcast accessible at: www.virtualshareholdermeeting.com/HUM2025

    Exercise your voting privilege as a Humana stockholder

    Humana associates who participate in our Company’s Retirement Savings Plan 401(k) and have invested funds in the Humana Common Stock Fund have the right to vote on items being presented at this year’s Annual Meeting, scheduled for April 17, 2025. You may submit one vote for each share held in your Humana Common Stock account as of February 28, 2025, the record date for this Annual Meeting.

    What documents do you need to vote?

    Every year, Humana produces a document - the proxy statement - that details all of the information the Company’s stockholders need in order to make informed votes. The proxy becomes available to stockholders and the public after Humana files it with the federal Securities and Exchange Commission on March 7, 2025. In order to vote, you must also receive an official “voting card.”

    When will you receive the proxy statement and voting card?

    Starting March 7, 2025, all stockholders who have (recently or in prior years) successfully submitted electronic requests for a proxy statement and voting card will then receive - via the e-mail address you designated during the online-registration process - a proxy statement and voting card. (Please watch for e-mail from [email protected].) If you did not sign up for electronic delivery of these materials, you’ll receive a “Notice and Access Card” in the mail at home regarding the material.

    When can participants in the Humana Retirement Savings Plan vote?

    If you wish to vote, you may do so AFTER you receive your voting card. You then must vote BEFORE 11:59 p.m., EDT on Wednesday, April 9, 2025, through Humana’s Retirement Savings Plan Trustee - Charles Schwab - with Broadridge acting as tabulator. If your voting instructions are received by 11:59 p.m. EDT on Wednesday, April 9, 2025, the Trustee will submit a proxy that reflects your instructions. If you do not give voting instructions (or give them late), the Trustee will vote your interest in the Humana Common Stock Fund in the same proportion as the shares attributed to the Humana Retirement Savings Plan actually voted. Humana’s Annual Meeting will be held on April 17, 2025.

    Whom do you contact for answers to your stockholder-voting-process questions?

    If you have any questions, please contact Joseph M. Ruschell, Corporate Secretary via email at [email protected].

    On March 7, 2025, the Company distributed the following “Notice Regarding the Availability of Proxy Materials” to its stockholders as of the record date of February 28, 2025.


    LOGO

     

    You invested in HUMANA INC. and it’s time to vote!

    You have the right to vote on proposals being presented at the Annual Meeting. This is an important notice regarding the availability of proxy materials for the stockholder meeting to be held on April 17, 2025.

    Get informed before you vote

    View the Notice and Proxy Statement and Annual Report online OR you can receive a free paper or email copy of the material(s) by requesting prior to April 3, 2025. If you would like to request a copy of the material(s) for this and/or future stockholder meetings, you may (1) visit www.ProxyVote.com, (2) call 1-800-579-1639 or (3) send an email to [email protected]. If sending an email, please include your control number (indicated below) in the subject line. Unless requested, you will not otherwise receive a paper or email copy.

     

    LOGO

     

     

    *Please check the meeting materials for any special requirements for meeting attendance.


    Vote at www.ProxyVote.com

     

     

    THIS IS NOT A VOTABLE BALLOT

     

    This is an overview of the proposals being presented at the upcoming stockholder meeting. Please follow the instructions on the reverse side to vote these important matters.

      

     

     

      Voting Items

     

     

    Board

    Recommends

     
      1.    Election of Directors  
     
       Nominees:  

      1a.

       Raquel C. Bono, M.D.   LOGO  For
     

      1b.

       Frank A. D’Amelio   LOGO  For
     

      1c.

       David T. Feinberg, M.D.   LOGO  For
     

      1d.

       Wayne A. I. Frederick, M.D.   LOGO  For
     

      1e.

       John W. Garratt   LOGO  For
     

      1f.

       Kurt J. Hilzinger   LOGO  For
     

      1g.

       Karen W. Katz   LOGO  For
     

      1h.

       Marcy S. Klevorn   LOGO  For
     

      1i.

       Jorge S. Mesquita   LOGO  For
     

      1j.

       James A. Rechtin   LOGO  For
     

      1k.

       Gordon Smith   LOGO  For
     

      2.

       The ratification of the appointment of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm.   LOGO  For
     

      3.

       Non-binding advisory vote for the approval of the compensation of the named executive officers as disclosed in the 2025 proxy statement.   LOGO  For
      At their discretion, the Proxies are authorized to vote upon any other matters as may come before the Annual Meeting.    
        

     

    Prefer to receive an email instead? While voting on www.ProxyVote.com, be sure to click “Delivery Settings”.

     

    V62002-P24548

    Get the next $HUM alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $HUM

    DatePrice TargetRatingAnalyst
    5/1/2025$315.00Mkt Perform → Outperform
    Raymond James
    11/6/2024$247.00 → $308.00Underperform → Neutral
    BofA Securities
    10/11/2024Sector Weight
    KeyBanc Capital Markets
    10/8/2024$308.00Mkt Perform → Outperform
    Bernstein
    10/7/2024$402.00 → $261.00Buy → Hold
    TD Cowen
    10/7/2024$519.00 → $253.00Buy → Hold
    Jefferies
    10/3/2024$392.00 → $274.00Overweight → Neutral
    Piper Sandler
    10/2/2024$376.00 → $247.00Neutral → Underperform
    BofA Securities
    More analyst ratings

    $HUM
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • CenterWell Specialty Pharmacy Takes National Patient Choice Award

      Organization Recognized for Seventh Time in Eight Years CenterWell Specialty Pharmacy has once again received the MMIT Specialty Pharmacy Patient Choice Award in the PBM/Payer category, its seventh such win in the past eight years. The award recognizes best-in-class customer satisfaction and commitment to patient care by a specialty pharmacy. "There's something so rewarding about seeing our team's dedication to excellent care and support being recognized year after year by the people we serve," said Guillermo Sollberger, senior vice president of CenterWell Specialty Pharmacy and CenterWell Pharmacy. "We know that many of the patients who require specialty drugs are feeling overwhelmed, so

      5/13/25 9:00:00 AM ET
      $HUM
      Medical Specialities
      Health Care
    • Humana Reports First Quarter 2025 Financial Results; Affirms Full Year 2025 Adjusted Financial Guidance

      Reports 1Q25 earnings per share (EPS) of $10.30 on a GAAP basis, Adjusted EPS of $11.58 1Q25 Insurance segment benefit ratio of 87.4 percent, in line with the company's previously disclosed expectation of 'approximately 87.5 percent' Affirms Adjusted FY 2025 EPS guidance of 'approximately $16.25'; while revising GAAP EPS to 'approximately $14.68' from the previous estimate of 'approximately $15.88' Affirms FY 2025 Insurance segment benefit ratio guidance range of 90.1 percent to 90.5 percent Affirms expected individual Medicare Advantage annual membership decline of approximately 550,000, inclusive of the impact of exiting certain unprofitable plans and counties Remains confident

      4/30/25 6:00:00 AM ET
      $HUM
      Medical Specialities
      Health Care
    • Humana Board Declares Payment of Quarterly Dividend to Stockholders

      Humana Inc. (NYSE:HUM) announced today that its Board of Directors has declared a cash dividend to stockholders of $0.885 per share payable on July 25, 2025 to stockholders of record as of the close of business on June 27, 2025. About Humana Humana Inc. is committed to putting health first – for our teammates, our customers, and our company. Through our Humana insurance services, and our CenterWell health care services, we make it easier for the millions of people we serve to achieve their best health – delivering the care and service they need, when they need it. These efforts are leading to a better quality of life for people with Medicare, Medicaid, families, individuals, military serv

      4/17/25 6:30:00 AM ET
      $HUM
      Medical Specialities
      Health Care

    $HUM
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Director Smith Gordon

      4 - HUMANA INC (0000049071) (Issuer)

      4/2/25 1:46:09 PM ET
      $HUM
      Medical Specialities
      Health Care
    • SEC Form 4 filed by Director Hilzinger Kurt J

      4 - HUMANA INC (0000049071) (Issuer)

      4/2/25 1:45:12 PM ET
      $HUM
      Medical Specialities
      Health Care
    • SEC Form 4 filed by Director Feinberg David T

      4 - HUMANA INC (0000049071) (Issuer)

      4/2/25 1:44:32 PM ET
      $HUM
      Medical Specialities
      Health Care

    $HUM
    SEC Filings

    See more
    • SEC Form 10-Q filed by Humana Inc.

      10-Q - HUMANA INC (0000049071) (Filer)

      4/30/25 9:29:51 AM ET
      $HUM
      Medical Specialities
      Health Care
    • Humana Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - HUMANA INC (0000049071) (Filer)

      4/30/25 6:05:50 AM ET
      $HUM
      Medical Specialities
      Health Care
    • Humana Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

      8-K - HUMANA INC (0000049071) (Filer)

      4/18/25 4:20:41 PM ET
      $HUM
      Medical Specialities
      Health Care

    $HUM
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Humana Inc. (Amendment)

      SC 13G/A - HUMANA INC (0000049071) (Subject)

      2/16/24 4:29:43 PM ET
      $HUM
      Medical Specialities
      Health Care
    • SEC Form SC 13G/A filed by Humana Inc. (Amendment)

      SC 13G/A - HUMANA INC (0000049071) (Subject)

      2/14/24 10:02:59 AM ET
      $HUM
      Medical Specialities
      Health Care
    • SEC Form SC 13G/A filed by Humana Inc. (Amendment)

      SC 13G/A - HUMANA INC (0000049071) (Subject)

      2/13/24 5:06:27 PM ET
      $HUM
      Medical Specialities
      Health Care

    $HUM
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Mesquita Jorge S. bought $200,066 worth of Humana Common (545 units at $367.09) (SEC Form 4)

      4 - HUMANA INC (0000049071) (Issuer)

      2/21/24 10:37:23 AM ET
      $HUM
      Medical Specialities
      Health Care

    $HUM
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Humana upgraded by Raymond James with a new price target

      Raymond James upgraded Humana from Mkt Perform to Outperform and set a new price target of $315.00

      5/1/25 7:42:13 AM ET
      $HUM
      Medical Specialities
      Health Care
    • Humana upgraded by BofA Securities with a new price target

      BofA Securities upgraded Humana from Underperform to Neutral and set a new price target of $308.00 from $247.00 previously

      11/6/24 8:21:46 AM ET
      $HUM
      Medical Specialities
      Health Care
    • KeyBanc Capital Markets initiated coverage on Humana

      KeyBanc Capital Markets initiated coverage of Humana with a rating of Sector Weight

      10/11/24 7:47:34 AM ET
      $HUM
      Medical Specialities
      Health Care

    $HUM
    Leadership Updates

    Live Leadership Updates

    See more
    • Humana Announces CFO Transition

      Leading health and well-being company Humana Inc. (NYSE:HUM) announced today that Celeste Mellet will be appointed to succeed Susan Diamond as Chief Financial Officer (CFO), effective January 11, 2025. Diamond is stepping down after a successful 18-year career at Humana, including over three years as CFO, and will serve in an advisory role through the end of 2025 to ensure a smooth transition. "On behalf of the entire Board and management team, I want to extend my thanks to Susan for her leadership as CFO and in prior roles during her nearly two decades at Humana," said Jim Rechtin, Humana's President and Chief Executive Officer. "Susan's contributions spanned across our Medicare, Home So

      12/3/24 8:05:00 AM ET
      $HUM
      Medical Specialities
      Health Care
    • Humana Appoints Michelle O'Hara as Chief Human Resources Officer

      Leading health and well-being company Humana Inc. (NYSE:HUM) announced today that it has named Michelle O'Hara as Chief Human Resources Officer, effective January 1, 2025. O'Hara will oversee the enterprise talent strategy and people programs for Humana's more than 63,000 employees. She brings a proven track record of transforming HR capabilities and enabling companies to effectively attract, recruit, develop and retain a talented and diverse workforce. O'Hara will report directly to Humana President and CEO Jim Rechtin. "Humana's people strategy is a core capability for our business that supports and empowers our workforce so they can successfully deliver on our mission to make it easier

      11/12/24 12:30:00 PM ET
      $HUM
      Medical Specialities
      Health Care
    • Define Ventures Appoints Bruce Broussard as Venture Partner

      The former Fortune 50 CEO joins Define to further drive transformational change in healthcare at the earliest stages of innovation SAN FRANCISCO, Oct. 22, 2024 /PRNewswire/ -- Define Ventures, one of the largest venture capital firms focused on early-stage health tech companies, today announced that Bruce Broussard, former CEO and president of Humana (NYSE:HUM), has joined the firm as venture partner. Bruce will play a pivotal role at Define, leveraging his invaluable experience scaling companies and fostering innovation within private startups, mid-size companies, and the Fortune 50. He will partner closely with Define founders to scale their businesses and become category-defining companie

      10/22/24 9:00:00 AM ET
      $EVH
      $HIMS
      $HUM
      Other Consumer Services
      Consumer Discretionary
      Medical/Nursing Services
      Health Care

    $HUM
    Financials

    Live finance-specific insights

    See more
    • Humana Reports First Quarter 2025 Financial Results; Affirms Full Year 2025 Adjusted Financial Guidance

      Reports 1Q25 earnings per share (EPS) of $10.30 on a GAAP basis, Adjusted EPS of $11.58 1Q25 Insurance segment benefit ratio of 87.4 percent, in line with the company's previously disclosed expectation of 'approximately 87.5 percent' Affirms Adjusted FY 2025 EPS guidance of 'approximately $16.25'; while revising GAAP EPS to 'approximately $14.68' from the previous estimate of 'approximately $15.88' Affirms FY 2025 Insurance segment benefit ratio guidance range of 90.1 percent to 90.5 percent Affirms expected individual Medicare Advantage annual membership decline of approximately 550,000, inclusive of the impact of exiting certain unprofitable plans and counties Remains confident

      4/30/25 6:00:00 AM ET
      $HUM
      Medical Specialities
      Health Care
    • Humana Board Declares Payment of Quarterly Dividend to Stockholders

      Humana Inc. (NYSE:HUM) announced today that its Board of Directors has declared a cash dividend to stockholders of $0.885 per share payable on July 25, 2025 to stockholders of record as of the close of business on June 27, 2025. About Humana Humana Inc. is committed to putting health first – for our teammates, our customers, and our company. Through our Humana insurance services, and our CenterWell health care services, we make it easier for the millions of people we serve to achieve their best health – delivering the care and service they need, when they need it. These efforts are leading to a better quality of life for people with Medicare, Medicaid, families, individuals, military serv

      4/17/25 6:30:00 AM ET
      $HUM
      Medical Specialities
      Health Care
    • Humana Inc. Announces Dates for First Quarter 2025 Earnings and June Investor Conference

      Humana Inc. (NYSE:HUM) will release financial results for the first quarter 2025 (1Q25) and host a live question-and-answer session on Wednesday, April 30, 2025. Additionally, the company will host an Investor Conference on Monday, June 16, 2025. 1Q25 Earnings Humana will release its 1Q25 financial results, as well as prepared management remarks (in PDF format), at 6:00 a.m. Eastern time on April 30, 2025. The company will host a live question-and-answer session at 8:00 a.m. Eastern time that morning to discuss its financial results for the quarter and earnings guidance for 2025. A webcast of the 1Q25 earnings call may be accessed via Humana's Investor Relations page at https://humana.gc

      4/3/25 4:15:00 PM ET
      $HUM
      Medical Specialities
      Health Care